Identification of a peptide antagonist of the FGF1–FGFR1 signaling axis by phage display selection

Overexpression of fibroblast growth factor receptor 1 ( FGFR 1) is a common aberration in lung and breast cancers and has necessitated the design of drugs targeting FGFR 1‐dependent downstream signaling and FGFR 1 ligand binding. To date, the major group of drugs being developed for treatment of FGFR 1‐dependent cancers are small‐molecule tyrosine kinase inhibitors; however, the limited specificity of these drugs has led to increasing attempts...